US Export Controls Backfire: USCBC Flash Survey Reveals Billions in Lost Sales and No Strategic Gain

A flash survey conducted by the US-China Business Council (USCBC) in July 2026 paints a stark picture of the Trump administration's export-control licensing regime: months-long delays are costing US companies billions of dollars in lost exports, eroding American market share globally, and achieving little-to-no strategic benefit . The survey captured responses from 31 companies primarily in the technology, industrial and manufacturing, energy, and healthcare sectors .

The Costs: Billions in Lost Sales and Market Share

The most frequently cited problem was the pace of license reviews. 95% of companies identified long review times as their top challenge, and 71% reported experiencing specific delays in obtaining licenses to export to China . Two-thirds of respondents (66%) have had licenses pending for at least three months, exceeding the Commerce Department's 90-day statutory requirement, while 31% reported licenses stuck in limbo for one to two years .

These delays carry a heavy price tag. More than a third (36%) of firms reported at least tens of millions of dollars in losses directly attributable to license delays, with multiple companies describing losses in the hundreds of millions or even billions . The ripple effects include:

• 73% lost sales to Chinese competitors
• 64% lost market share in China
• 55% lost sales to international competitors outside China

Average processing times at the Bureau of Industry and Security (BIS) have slowed markedly: 62 days in 2025, up from 38 days in 2023 .

No Strategic Gain: The Foreign Availability Problem

The survey's central finding undercuts the core justification for the controls. 82% of respondents said their pending export licenses cover items for which comparable alternatives from non-US suppliers are readily available .

Breaking that 82% down:

• 64% reported alternatives from both Chinese and international suppliers
• 9% from an international supplier only
• 9% from a Chinese supplier only

The implication is clear: denying a US company a license to sell a product to a Chinese customer does not prevent that customer from obtaining the same product from a competitor in China, Europe, or elsewhere. The USCBC report describes the controls as "poorly calibrated" — they weaken American companies in China, cede market share to foreign competitors, reduce profits available for R&D, and ultimately "diminish America's ability to innovate and undermine US economic security" .

Procedural Breakdown: Communication and Engagement Failures

Beyond delays, companies reported serious procedural breakdowns in the licensing process:

• 57% cited unreliable communication from licensing officers
• 48% cited unclear policy interpretations
• 50% pointed to the lack of Technical Advisory Committee (TAC) meetings as the primary procedural challenge; BIS has curtailed most TAC engagement since 2025, removing a key channel for industry input on technical details
• 85% said reinstating the suspended Affiliates Rule would have a severe or moderate impact on their businesses — a rule that previously allowed certain license-free transfers among affiliated companies

Chinese Retaliation Adds Pressure

The survey also flagged risks that go beyond US policy. 27% of respondents reported retaliatory actions by the Chinese government in their sector, including withholds or delays in approvals related to rare earths .

The Bigger Picture: A Self-Inflicted Wound

The broader USCBC Member Survey 2026, which collected 175 responses, adds context: 95% of US companies still say China operations are somewhat to very important for staying globally competitive . Yet roughly half of firms affected by export controls reported lost sales to Chinese or international competitors . The USCBC's assessment is blunt — regulators are "handicapping America's most innovative companies and ceding ground to competitors without meaningfully advancing US national security" .